Atractylenolide I mitigates Alzheimer's disease pathology in ApoE (-/-) mice via ARG1/nNOS axis and lipid homeostasis regulation.

Apolipoprotein E (ApoE) serves as a critical molecular nexus between Alzheimer's disease (AD) and atherosclerosis, two age-associated inflammatory disorders that share vascular pathology, amyloid-beta (Aβ) deposition, and lipid dysregulation. Atractylenolide I (AI), a promising therapeutic candidate derived from